BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Salvati A, Poelstra K. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation. Pharmaceutics 2022;14:217. [DOI: 10.3390/pharmaceutics14010217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Grossman M, Adler E. Protein Kinase Inhibitors - Selectivity or Toxicity? Protein Kinases - Promising Targets for Anticancer Drug Research 2021. [DOI: 10.5772/intechopen.98640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ogawa H, Kaji K, Nishimura N, Takagi H, Ishida K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. J Cell Mol Med 2021;25:4001-13. [PMID: 33609067 DOI: 10.1111/jcmm.16363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen X, Zhang D, Wang Y, Chen K, Zhao L, Xu Y, Jiang H, Wang S. Synergistic antifibrotic effects of miR-451 with miR-185 partly by co-targeting EphB2 on hepatic stellate cells. Cell Death Dis 2020;11:402. [PMID: 32467578 DOI: 10.1038/s41419-020-2613-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Poelstra K. Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Curr Tissue Microenviron Rep 2020;1:13-22. [DOI: 10.1007/s43152-020-00004-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Fan QQ, Zhang CL, Qiao JB, Cui PF, Xing L, Oh YK, Jiang HL. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials 2020;230:119616. [PMID: 31837823 DOI: 10.1016/j.biomaterials.2019.119616] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
7 Mohammadalipour A, Hashemnia M, Goudarzi F, Ravan AP. Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis. Clin Exp Pharmacol Physiol 2019;46:1183-93. [PMID: 31396972 DOI: 10.1111/1440-1681.13157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jiang Y, Zhao Y, He F, Wang H. Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice. Hum Gene Ther 2019;30:179-96. [PMID: 30024280 DOI: 10.1089/hum.2018.047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
9 Zhu D, Hu B, Zhou Y, Sun X, Chen J, Chen L, Ji Z, Zhu J, Duan Y. microRNA-146a is involved in rSjP40-inhibited activation of LX-2 cells by targeting Smad4 expression. J Cell Biochem 2018;119:9249-53. [PMID: 29953648 DOI: 10.1002/jcb.27193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 El-mezayen NS, El-hadidy WF, El-refaie WM, Shalaby T, Khattab MM, El-khatib AS. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. Journal of Controlled Release 2017;266:226-37. [DOI: 10.1016/j.jconrel.2017.09.035] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]